Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo Rispens

Showing results (181-190 of 304) with videos related to

Pageof 31
Sort By:
RMD Open|April 20, 2024
Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatologyYaëlle R Besten, Laura Boekel, Maurice Steenhuis, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 29, 2018
Structural Basis of Cross-Reactivity of Anti-Citrullinated Protein AntibodiesChangrong Ge, Bingze Xu, Bibo Liang, et al.
JAMA Neurology|March 31, 2025
Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple SclerosisLiza M Y Gelissen, Martijn T Wijburg, Eva M M Strijbis, et al.
Elife|March 2, 2023
Single-cell analysis reveals dynamics of human B cell differentiation and identifies novel B and antibody-secreting cell intermediatesNiels J M Verstegen, Sabrina Pollastro, Peter-Paul A Unger, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 24, 2023
Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosisAlyssa A Toorop, Laura Hogenboom, Karien Bloem, et al.
Allergy|July 15, 2022
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitisLotte S Spekhorst, Daphne Bakker, Julia Drylewicz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 2, 2017
Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor ProfileChristine W Bruggeman, Gillian Dekkers, Arthur E H Bentlage, et al.
The Journal of Investigative Dermatology|August 22, 2018
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort StudyNina Wilkinson, Teresa Tsakok, Nick Dand, et al.
Frontiers in Immunology|July 21, 2025
The TNFα-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patientsMateusz Makuch, Josine van Beek, Carla A Wijbrandts, et al.
Nature Communications|October 14, 2022
The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagementMaximilian Brinkhaus, Erwin Pannecoucke, Elvera J van der Kooi, et al.
Pageof 31

Showing results (181-190 of 304) with videos related to

Sort By:
Pageof 31
RMD Open|April 20, 2024
Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatologyYaëlle R Besten, Laura Boekel, Maurice Steenhuis, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 29, 2018
Structural Basis of Cross-Reactivity of Anti-Citrullinated Protein AntibodiesChangrong Ge, Bingze Xu, Bibo Liang, et al.
JAMA Neurology|March 31, 2025
Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple SclerosisLiza M Y Gelissen, Martijn T Wijburg, Eva M M Strijbis, et al.
Elife|March 2, 2023
Single-cell analysis reveals dynamics of human B cell differentiation and identifies novel B and antibody-secreting cell intermediatesNiels J M Verstegen, Sabrina Pollastro, Peter-Paul A Unger, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 24, 2023
Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosisAlyssa A Toorop, Laura Hogenboom, Karien Bloem, et al.
Allergy|July 15, 2022
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitisLotte S Spekhorst, Daphne Bakker, Julia Drylewicz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 2, 2017
Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor ProfileChristine W Bruggeman, Gillian Dekkers, Arthur E H Bentlage, et al.
The Journal of Investigative Dermatology|August 22, 2018
Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort StudyNina Wilkinson, Teresa Tsakok, Nick Dand, et al.
Frontiers in Immunology|July 21, 2025
The TNFα-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patientsMateusz Makuch, Josine van Beek, Carla A Wijbrandts, et al.
Nature Communications|October 14, 2022
The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagementMaximilian Brinkhaus, Erwin Pannecoucke, Elvera J van der Kooi, et al.
Pageof 31